Dogwood Therapeutics (DWTX) Investor presentation summary

Executive leadership and experience

• Leadership team includes executives with backgrounds at Pfizer, UCB, and Celtaxsys, with experience in developing and commercializing major drugs such as Zoloft, Viagra, Lipitor, Aricept, Celebrex, Lyrica, and Cimzia.

Pipeline and clinical development

• Advancing two first-in-class, non-opioid pain and neuropathy candidates: Halneuron (Nav1.7 inhibitor, Phase 2b) and SP16 (LRP1 agonist, Phase 1b).

• Halneuron targets moderate-to-severe neuropathic pain, especially chemotherapy-induced neuropathic pain (CINP), with FDA fast-track designation.

• SP16 is positioned for neuroprotection and anti-inflammatory effects, with NCI-funded clinical development.

Market opportunity and unmet need

• No FDA-approved treatments for CINP; current market estimated at $3B in the US, with 1.15 million patients and projected 53% growth in the next decade.

• Halneuron addresses a significant unmet need, with prior CINP trials largely unsuccessful and off-label drugs proving ineffective.